International Edition
Latest News
Health

Chlorhexidine Catheter Coating Allergy, GLP-1 Switch Reaction, Menopausal VIT Loss at ACAAI 2026

“Our findings suggest the need for awareness of chlorhexidine coating in medical devices,” researchers noted, Medscape reported on Monday, highlighting three complex clinical cases presented at the American College of Allergy, Asthma, and Immunology 2026 Annual Meeting. A…

Chlorhexidine Catheter Coating Allergy, GLP-1 Switch Reaction, Menopausal VIT Loss at ACAAI 2026

“Our findings suggest the need for awareness of chlorhexidine coating in medical devices,” researchers noted, Medscape reported on Monday, highlighting three complex clinical cases presented at the American College of Allergy, Asthma, and Immunology 2026 Annual Meeting.

A 39-year-old woman undergoing surgery for an abdominal aortic aneurysm developed hypotension, hypoxemia, bronchospasm, and cardiac arrest within 2 minutes of a central venous catheter being placed, according to case reports presented at the meeting. Diagnostic testing confirmed a chlorhexidine allergy after the patient received cardiopulmonary resuscitation and epinephrine.

During a rescheduled procedure, clinicians used povidone-iodine to avoid chlorhexidine exposure. However, the patient experienced recurrent hypotension, hypoxemia, and bronchospasm after a new central venous catheter was placed because the surgical team had not recognized that the device itself contained a chlorhexidine coating.

The patient stabilized after receiving epinephrine, corticosteroids, and antihistamines. Nawshin Jamil, DO, of Lowell General Hospital in Lowell, Massachusetts, and colleagues detailed the case to demonstrate how device coatings can trigger perioperative anaphylactic shock even when clinicians actively avoid known antiseptic agents.

GLP-1 Agonist Switch Triggers Allergy

In a separate presentation, Victoria Hough of the Mayo Clinic in Jacksonville, Florida, and colleagues described a patient who tolerated compounded semaglutide for a year before developing hypersensitivity after switching to compounded tirzepatide. Prior tolerance to one GLP-1 receptor agonist does not preclude severe reactions to another, and the authors suggested that clinicians avoid premature class-wide labeling of allergies.

The 38-year-old woman with obesity changed medications because her weight loss had plateaued. A rechallenge with tirzepatide resulted in escalating reactions over 8 days, including progressive injection-site urticaria that required emergency department treatment with intravenous corticosteroids.

The patient subsequently developed lip and periorbital angioedema requiring epinephrine in the emergency department, followed by facial and hand angioedema with voice changes and generalized urticaria that prompted self-administration of epinephrine. Symptoms resolved within 3 days after treatment with high-dose corticosteroids, a 6-week taper, and histamine-1 and histamine-2 receptor blockers.

“Tirzepatide, excipients, or compounded formulation differences remain possible contributors,” the authors stated regarding the exact culprit behind the reaction.

Menopause Disrupts Venom Immunotherapy

Menopause precipitated a loss of tolerance to established allergen immunotherapy in a 51-year-old woman who had successfully maintained honeybee venom immunotherapy for several years, according to a case report co-authored by David Engler, MD, of Houston. Subsequent attempts to continue immunotherapy with high-dose antihistamine therapy failed, resulting in three episodes of grade 4 anaphylaxis with loss of consciousness.

Mayo Clinic is a private American academic medical center founded in 1864 by William Worrall Mayo in Rochester, Minnesota. It now operates major campuses in Jacksonville, Florida, and Phoenix/Scottsdale, Arizona, employing more than 7,300 physicians and scientists alongside 66,000 administrative and allied health staff.

The nonprofit system spends over $660 million annually on research and has been ranked number one in the United States by U.S. News & World Report for eight consecutive years.

Each episode required treatment with epinephrine, leading clinicians to discontinue venom immunotherapy. “Postmenopausal status may alter mast cell activation thresholds, providing a biologically plausible mechanism,” the authors said.

About the author: Health Desk

Health Desk at Archynewsy.